Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report
Open Access
- 23 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 6 (10) , ytac396
Abstract
Background: Cancer therapy–related cardiac dysfunction (CTRCD) is a challenging and life-threatening complication of many chemotherapeutic regimens. CTRCD prevention, diagnosis, and therapy require both careful interdisciplinary assessment and management. For patients with CTRCD, current guidelines of the European Society of Cardiology (ESC) recommend an angiotensin-converting-enzyme inhibitor in combination with a beta-blocker. Recent studies indicate a beneficial effect of sacubitril/valsartan in this patient population. Case summary: A 68-year-old female patient with a pleural epithelioid angiosarcoma developed heart failure with reduced ejection fraction and elevated serum biomarkers following doxorubicin treatment. After implementation of a recommended cardioprotective medical therapy including torasemide, ramipril, carvedilol, and spironolactone, the patient suffered two cardiac decompensations within 4 weeks after initiation of a paclitaxel regimen and pleural radiation therapy due to pain exacerbation. Despite a continuous application of the cardioprotective medical treatment regimen, no improvement of left-ventricular ejection fraction (LVEF) was detected in a 4-month follow up. Interestingly, after omitting ramipril and implementing low-dose sacubitril/valsartan (26/24 mg), we observed a decrease in serum biomarkers within 3 months as well as a significant improvement of LVEF within 6 months. After nearly 10 months of disease stabilization under paclitaxel, the patient suffered progressive cancer disease and deceased 1 week later after the initiation of a therapeutic attempt with pazopanib. Discussion: This case report highlights the importance of interdisciplinary care in cancer patients as well as the promising role of (low-dose) sacubitril/valsartan in patients with CTRCD even in the setting of delayed initiation.Keywords
Funding Information
- German Federal Ministry for Education (01EO1503)
- Boehringer Ingelheim Foundation
This publication has 14 references indexed in Scilit:
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Cardiotoxicity of AnthracyclinesFrontiers in Cardiovascular Medicine, 2020
- Remodelado ventricular tras el uso de sacubitrilo-valsartán en la miocardiopatía tóxica del paciente con cáncerRevista Espanola de Cardiologia, 2020
- Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathyRevista Española de Cardiología (English Edition), 2020
- Effectiveness of Sacubitril–Valsartan in Cancer Patients with Heart FailureESC Heart Failure, 2020
- Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registryEuropean Heart Journal, 2020
- The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case seriesJournal of Oncology Pharmacy Practice, 2018
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Anthracycline-Induced CardiomyopathyJACC, 2010